Progesterone is typically discussed in the context of menstrual cycle regulation and early pregnancy, but it has significant neurological effects that are less widely known. It acts on GABA receptors in the brain, the same receptors targeted by benzodiazepines and alcohol, producing calming and sleep-promoting effects. It also raises body temperature slightly, which supports the temperature drop needed for sleep onset. When progesterone declines in perimenopause, often years before oestrogen begins its more dramatic fall, the sleep disruption is one of the first and most consistent symptoms.
Why Perimenopausal Sleep Disruption Is Different
Women in perimenopause frequently describe a specific pattern of sleep disruption: falling asleep easily, then waking at 2am or 3am with racing thoughts, an inability to return to sleep, and disproportionate anxiety. This pattern is characteristic of progesterone deficiency. Progesterone suppresses the HPA axis and reduces cortisol reactivity; when it falls, overnight cortisol is less well regulated, producing the characteristic 3am awakening.
The Case for Micronised Progesterone
Micronised progesterone, sold as Utrogestan in the UK, is chemically identical to the progesterone the body produces, unlike synthetic progestins such as medroxyprogesterone acetate. The evidence consistently shows that micronised progesterone has significantly better sleep effects than synthetic progestins, and a more favourable safety profile for breast tissue. NICE guidelines now recommend micronised progesterone as the preferred progestogen for HRT in women who require uterine protection.
Sources
- Caufriez, A., et al. (2011). Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 96(4), E614-E623.
- de Lignieres, B., et al. (2002). Oral micronized progesterone. Clinical Obstetrics and Gynecology, 38(4), 893-905.
- Prior, J.C. (2018). Progesterone is important for transgender women's therapy. Journal of Clinical Endocrinology and Metabolism, 104(4), 1181-1186.